March 25, 2021: HIV disease progression spikes in a London hospital; neurocognitive impairment and frailty in PLWH; the smell of HIV-associated neurocognitive disorder; statin usage and physical function decline.
A new study shows that almost two-thirds of older adults who were diagnosed with HIV at a Connecticut clinic were already at an advanced stage of disease progression.
Feb. 25, 2021: High HCV SVR among people using substances; geographic HIV care disparities among Black Americans; self-administered imiquimod vs. ASIL excision; PrEP uptake in syringe service programs.
Even among people on modern HIV treatment, just over a quarter of PLWH are diagnosed with dementia by age 80, compared to just under 14% of HIV-negative people, according to a new U.S. study.
“Telling them now that ‘the government is saying I need to decrease your opioids. ... Sorry you’re going to suffer,’ was just not satisfying to me as a physician,” says Maile Young Karris, M.D.
Oct. 8, 2020: HPV-related cancer risk among women living with HIV; the interplay between HIV, HBV, and liver disease; Framingham vs. other tools to gauge statin value; integrase inhibitors, weight gain, and menopause.
Sept. 17, 2020: HIV prevalence gaps between Latinx people and non-Latinx white people; Obamacare awareness and perceptions among HIV clinicians; the relationship between pain and HIV; cancer mortality trends among PLWH.
Aug. 6, 2020: Recent trends in drug interaction rates; integrase inhibitors and cardiac event risk; a deep dive into HIV drug resistance in Florida; frailty symptoms and neurocognitive disorders amidst high CD4 counts.
A Chicago survey of people over 60 finds high self-reported viral suppression rates—but also clear signs that people need help navigating a range of other physical and mental health concerns.
June 4, 2020: The latest on COVID-19 hospitalization among people with HIV; real-world success of hepatitis C treatment in coinfected patients with good health care; poverty and adherence in Canada's health system; demographic and socioeconomic factors associated with viral rebound.